Biotech Startups

Pacify Medical develops biomedical devices for wound management, specifically surgical and trauma wound care. The company's flagship product is a patent-protected skin spray device designed to improve wound healing outcomes.

1 investor

Pacira develops and commercializes non-opioid therapies for postsurgical, chronic, and musculoskeletal pain, and is advancing a gene therapy pipeline candidate. It serves patients and healthcare providers seeking alternatives to opioid pain management.

1 investor

PACIV provides industrial automation controls, instrumentation, and system validation services for biotechnology, pharmaceutical, medical device, food & beverage, and utilities sectors. The company operates across the United States, Puerto Rico, and Ireland with local teams supporting client-specific automation platform implementations.

1 investor

Padagis manufactures prescription and over-the-counter topical and other non-oral pharmaceutical products, including creams, ointments, gels, foams, sprays, patches, nasal treatments, and suppositories, with a specialization in Paragraph IV generic products. It serves patients and healthcare providers, and partners with companies through licensing, joint ventures, marketing, and contract manufacturing.

1 investor

PAhR Therapeutics is a clinical-stage biotech company developing novel mechanisms to treat pulmonary arterial hypertension (PAH).

1 investor

PAION AG is a company whose business operations were sold in a finalised sale process in early 2024. The available page content consists of investor news announcements and does not describe the company's products or activities in detail.

1 investor

PAK BioSolutions builds automated systems and single-use flow kits for end-to-end continuous purification of biopharmaceuticals, running four continuous purification stages simultaneously for a stated 4X productivity gain over batch methods. Its equipment and GMP consumables serve biopharmaceutical manufacturers for both laboratory and GMP production.

1 investor

Paleo develops plant-based protein products designed to replicate the taste and qualities of animal meat, addressing sustainability in food production. The company targets food producers and consumers seeking sustainable protein alternatives.

1 investor

Palisade Bio develops a PDE4 prodrug platform for treating immune, inflammatory, and fibrotic diseases, with improved pharmacokinetics and tolerability compared to traditional PDE4 inhibitors. The company's lead candidate is designed for once-daily dosing with reduced gastrointestinal side effects.

1 investor

1 investor

Palm Therapeutics develops palmitoylation-targeted drugs using its proprietary PalmReader screening platform to identify novel therapeutic molecules. The company focuses on modulating protein palmitoylation, a post-translational modification involved in multiple disease pathways.

1 investor

Palto Therapeutics develops formulations for biological drugs, focusing on oligonucleotide therapeutics such as siRNAs and antisense oligonucleotides that deliver directly into diseased cells and activate in the cytoplasm. It works on proprietary delivery and formulation strategies aimed at addressing in vivo stability and targeted tissue/cell distribution for these next-generation drugs.

1 investor

Panacea-ml provides clinical development data analytics to pharmaceutical companies and contract research organizations, helping them design and conduct clinical trials more efficiently by identifying optimal trial participants and predicting adverse outcomes.

1 investor

Panacea Capital is a venture capital firm, spun out from Kleiner Perkins, that invests in life sciences and healthcare innovation across all geographies. It has raised three USD funds and holds stakes in more than 30 private companies and several public companies, spanning company formation, expansion-stage, and public-market investing.

1 investor

Pando develops enzyme design and optimization using machine learning to accelerate the design-build-test-learn cycle for biotechnology applications.

1 investor

Pangolin Therapeutics develops Pangomers, synthetic molecules designed to target and interfere with intrinsically disordered proteins involved in Type 2 Diabetes, neurodegeneration, and cancer. The company uses molecular modeling and drug discovery tools to create therapeutics for previously undruggable protein targets.

1 investor

panluminate develops instruments and processes for whole-brain connectomic mapping at scale, using its pan-ExM imaging technique to capture both neural wiring and molecular state simultaneously at 15nm resolution. It serves neuroscience research institutions with products and services that combine high-resolution microscopy and AI-based segmentation of brain circuitry.

1 investor

Pano Therapeutics develops small-molecule drug candidates targeting mitochondrial dysfunction, with a lead program in Fragile X Syndrome and neurodevelopmental disorders. The company's approach builds on metformin's mechanisms and is designed to serve patients with syndromic neurodevelopmental disorders.

1 investor

Panoptic.bio monitors global clinical trial registries, tracks events that affect drug development programs, and builds models to predict what happens next across discovery, trials, manufacturing, and distribution. It positions itself as a "digital twin pharma company" offering tools to track clinical trials for the pharmaceutical and clinical development sector.

1 investor

1 investor

Panoptive provides a software platform that continuously monitors clinical trials by converting monitoring reports and electronic data capture (EDC) data into structured findings, documented decisions, and audit-ready oversight records. The platform serves sponsors and clinical operations teams conducting regulated trials and helps organizations surface quality issues early while maintaining inspection-ready documentation.

1 investor

PanTheryx is a health and nutrition company that develops and commercializes consumer health supplements for the human health and wellness market, including products for digestive support and dietary needs.

1 investor

Panthura develops non-viral DNA delivery technology for sustained therapeutic effects in specific tissues, with potential for repeated administration. The company is advancing its platform through preclinical and clinical development stages.

1 investor

Paques designs and delivers biological treatment systems that purify wastewater, recover reusable materials, produce biogas, and desulfurize gas for commercial industries and water service providers. Operating since 1981, the company has installed over 3,400 water purification systems across more than 60 countries.

1 investor